BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 31, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Selective POLθ inhibitor enhances response to PARP inhibition in HR-deficient tumor models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Selective POLθ inhibitor enhances response to PARP inhibition in HR-deficient tumor models
Oct. 29, 2024
No Comments
Moma Therapeutics Inc. has reported preclinical results on MOMA-313, a potent and selective DNA polymerase θ (POLθ) inhibitor under development for the treatment of homologous recombinant (HR)-deficient cancers.
BioWorld Science
Conferences
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Cancer
